Hypofractionated radiotherapy denoted as the “Christie scheme”: An effective means of palliating patients with head and neck cancers not suitable for curative treatment

References

• Steel, GG. Basic clinical radiobiology. 3rd ed. New York: Hodder Arnold; 2002.
   Google Scholar
• Paterson R. Studies in optimum dosage. Br J Radiol 1952; 25: 505–16
   PubMed Web of Science ®Google Scholar
• Schofield CP, Sykes AJ, Slevin NJ, Rashid NZZ. Radiotherapy for head and neck cancer in elderly patients. Radiother Oncol 2003; 69: 37–42
   PubMedGoogle Scholar
• Weissberg JB, Son YH, Percarpio B, Fischer JJ. Randomized trial of conventional versus high fractional dose radiation therapy in the treatment of advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1982; 8: 179–85
   PubMed Web of Science ®Google Scholar
• Corry JF, Peters LJ, D'Costa I, Milner AD, Fawns H, Rischin D, et al. The “Quad Shot”– a phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother Oncol 2006; 77: 137–42
   Google Scholar
• Henk JM, James KW. A comparative trial of large and small fractions. Br J Radiol 1976; 49: 1055–6
   Google Scholar
• Porceddu SV, Rosser B, Burmeister BH, Jones M, Hickey B, Baumann K, et al. Hypofractionated radiotherapy for the palliation of advanced head and neck unsuitable for curative treatment – “Hypo Trial”. Radiother Oncol 2007; 85: 456–62
   PubMedGoogle Scholar
• Wierink G, Alcock CJ, Bated TD, Brindle JM, Fowler JF, Gajek WR, et al. Final report on the second British Institute of Radiology fractionation study: Short versus long overall treatment times for radiotherapy of carcinoma of the laryngopharynx. Br J Radiol 1991; 64: 232
   PubMedGoogle Scholar
• Gowda RV, Henk JM, Mais KL, Sykes AJ, Swindell R, Slevin NJ. Three weeks radiotherapy for T1 glottic cancer: The Christie and Royal Marsden Hospital experience. Radiother Oncol 2003; 68: 105–11
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and European Organisation for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341–6
   PubMed Web of Science ®Google Scholar
• Bjordal, K, de Graeff, A, Fayers, PM, Hammerlid, E, van Pottelsberghe, Curran, D, , et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 2000; 36:1796–807.
   PubMed Web of Science ®Google Scholar
• Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer 2000; 36: 1032–7
   PubMed Web of Science ®Google Scholar
• Laskar SG, Agarwal JP, Srinivas C, Dinshaw KA. Radiotherapeutic management of locally advanced head and neck cancer. Expert Rev Anticancer Ther 2006; 6: 405–17
   PubMed Web of Science ®Google Scholar
• Bonner JA, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Eng J Med 2006; 354: 567–78
   PubMed Web of Science ®Google Scholar
• Levendag PC, Nowak PJ, van der Sangen MJ, Jansen PP, Eijkenboom WM, Planting AS, et al. Local tumor control in radiation therapy of cancers in the head and neck. Am J Clin Oncol 1996; 19: 469–77
   PubMedGoogle Scholar
• Baatenburg de Jong RJ, Hermans J, Molenaar J, Briaire JJ, le Cessie S. Prediction of survival in patients with head and neck cancer. Head Neck 2001; 9: 718–24
   Google Scholar
• Mendenhall WM, Parsons JT, Mancuso AA, Stringer SP, Cassisi NP. Radiotherapy for squamous cell carcinoma supraglottic larynx: An alternative to surgery. Head Neck 1996; 18: 24–35
   PubMedGoogle Scholar
• Mendenhall WM, Parson JT, Million RR, Fletcher GH. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiation: Relationship of dose-fractionation factors for local control and complications. Int J Radiat Oncol Biol Phys 1988; 15: 1267–73
   PubMed Web of Science ®Google Scholar
• Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984; 54: 811–4
   PubMed Web of Science ®Google Scholar